MannKind Corporation Reports 2019 Fourth Quarter and Full Ye

[ktim]

Feb 25, 2020 22:06:26 GMT -5 brotherm1 said:

There have been a steady amount of trades after hours for some time now, fairly many shares from open to close, at variant prices (maybe 30k plus per day for a couple of months I think?). Not a lot but the after hours trading has been like every day. And there did appear to me there was accumulation in recent months with a bit of an increased volume throughout the days. Perhaps we will see a 5% form filed soon from other than an investment company. Fingers crossed though I think I’m having an epiphany on this bar stool.

That's something we can all agree upon. 

[lennymnkd]

United therapeutics earnings call @9:30 maybe they will say what Mnkd could not say.

[Clement]

Feb 26, 2020 5:45:22 GMT -5 lennymnkd said:

United therapeutics earnings call @9:30 maybe they will say what Mnkd could not say.

at 9:00 am

[boca1girl]

Feb 25, 2020 22:14:36 GMT -5 brotherm1 said:

Would UTHR be interested in the migraine drug we have?

MC said he has talked to Lilly about this drug since their’s is going to lose patent protection soon.  From the transcript, page 4.

As an IV-like response, just like we see in Afrezza and the other products, we put on our platform. We're very excited about this preliminary data albeit animal. Usually for us, this is indicative of the direction we go as we go through dosing and toxicity studies. This program ultimately licensed out to a partner or spun out of the company. And if we can't find a partner for some reason and at that point, we wouldn't invest any more MannKind resources in it. However, we think it's prudent to get us to a certain age, so that a partner can see the data and understand the value that this will bring in a unique market. And many people will say that sumatriptan is crowded generics. I'll just highlight that Lilly and I believe Allergan has recently launched two new sumatriptan in that marketplace. So a lot happening in the migraine space and chronic prevention. We believe there's still a need for an acute treatment as we look forward.

[morfu]

I18 II18 III18 IV18 I19 II19 III19 IV19
Total revenues 3.4 3.8 4.4 16.0 17.5 15.0 14.6 16.0
of which
Afrezza net 3.4 3.8 4.4 5.7 5.0 6.1 6.4 7.8
collaboration 10.3 12.4 8.9 8.2 8.2

liane´s table 6.5 8.4 10 11.5 12.2 13.2 13.3 17.2
Anet over table .52 .45 .44 .50 .45 .46 .48 0.45

Afrezza gross profit -0.6* -1.3 0.7 1.1 1.7 2.1 3.1
R&D expenses -2.6 -3.0 2.0 -1.1 -1.7 -1.6 -1.6 -2.0
SG&A -15.4 -21.7-19.4 -18.0 -27.7 -16.6 -16.7 -15.7
Interest expense -1.8 -1.7 -1.0 -0.6 -0.6 -0.6 -4.1 -2.3
net loss -30.4 -22.7 -24.2 -9.7 -14.9 -12.4 -10.4 -14.3
Cash 27.2 53.1 11.0 71.7 59.8 38.2** 50.4 50.2

*Sanofi buyout??
**38.2+75 new credits, 40 of this came in Aug19

[JEvans]

MC said in the call, as I remember, when he was talking about Affreza sales.....that he would like to see weekly Trx go up to a 1,000 and I just thought, crap!  He's setting his sights kinda low.

I was hoping for 4,000-5,000

[ktim]

Feb 27, 2020 1:05:01 GMT -5 JEvans said:

MC said in the call, as I remember, when he was talking about Affreza sales.....that he would like to see weekly Trx go up to a 1,000 and I just thought, crap!  He's setting his sights kinda low.

I was hoping for 4,000-5,000

Not that he would like it at some point, but saying he expected it in 2020.

[mytakeonit]

Probably more like a break even point without having to include international sales.

But, that's mytakeonit

[morfu]

Feb 26, 2020 23:05:42 GMT -5 morfu said:

                        I18         II18          III18 IV18 I19 II19 III19 IV19
Total revenues 3.4 3.8 4.4 16.0 17.5 15.0 14.6 16.0
of which
Afrezza net 3.4 3.8 4.4 5.7 5.0 6.1 6.4 7.8
collaboration 10.3 12.4 8.9 8.2 8.2

liane´s table 6.5 8.4 10 11.5 12.2 13.2 13.3 17.2
Anet over table .52 .45 .44 .50 .45 .46 .48 0.45

Afrezza gross profit -0.6* -1.3 0.7 1.1 1.7 2.1 3.1
R&D expenses -2.6 -3.0 2.0 -1.1 -1.7 -1.6 -1.6 -2.0
SG&A -15.4 -21.7-19.4 -18.0 -27.7 -16.6 -16.7 -15.7
Interest expense -1.8 -1.7 -1.0 -0.6 -0.6 -0.6 -4.1 -2.3
net loss -30.4 -22.7 -24.2 -9.7 -14.9 -12.4 -10.4 -14.3
Cash 27.2 53.1 11.0 71.7 59.8 38.2** 50.4 50.2

*Sanofi buyout??
**38.2+75 new credits, 40 of this came in Aug19

Let´s typeset it a little better:

                            I18         II18         III18         IV18         I19         II19         III19         IV19
Total revenues     3.4         3.8         4.4             16.0         17.5         15.0         14.6         16.0
of which
Afrezza net         3.4         3.8             4.4         5.7             5.0         6.1             6.4         7.8
collaboration                                                         10.3         12.4         8.9         8.2         8.2

liane´s table     6.5         8.4             10             11.5         12.2         13.2         13.3         17.2
Anet over table .52         .45             .44             .50         .45             .46         .48             .45

Afrezza gross profit -            0.6* -1.3         0.7             1.1             1.7            2.1             3.1
R&D expenses -2.6         -3.0         2.0         -1.1             -1.7         -1.6         -1.6             -2.0
SG&A             -15.4         -21.7        -19.4     -18.0         -27.7         -16.6         -16.7         -15.7
Interest expense -1.8     -1.7         -1.0         -0.6         -0.6             -0.6         -4.1             -2.3
net loss         -30.4         -22.7         -24.2     -9.7         -14.9         -12.4         -10.4         -14.3
Cash                 27.2         53.1         11.0        71.7     59.8             38.2         50.4             50.2

Hmm, I realize more and morethat these number are incomplete.. for example the net loss is higher this quarter due to some debt restruturing,

The cash is virtually unchanged, but I think a milestone payment is the reason for that..